Citations

Clear

4847 citation(s) found for "Tu, Eric".

Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Qin, Kang , Li, Shenduo , Hong, Lingzhi , Padmakumar, Priyadharshini, Waree, Rinsurongkawong, Le, Xiuning , Vokes, Natalie I. , Vaporciyan, Ara A. , Lee, J. Jack , Jaffray, David A. , Altan, Mehmet , Lou, Yanyan , Zhang, Jianjun , Hong, Lingzhi , Le, Xiuning , Lee, J Jack , Zhang, Jianjun , Wang, Kaiwen , Hubert, Shawna Marie , Rai, Kunal , Gibbons, Don L , Heymach, John V. , Woodman, Scott Eric , Chung, Caroline , Vokes, N.

Mayo Clinic

Cancers | February 26, 2024 | Volume: 16 | Issue: 5 | Pages: 935

10.3390/cancers16050935 | PMID 38473297 Get It

Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramucirumab. We also investigated whether platinum/taxane-based regimens offered a better clinical benefit in this patient population. A total of 454 patients were analyzed (docetaxel +/− ramucirumab n=381; platinum/taxane-based regimens n=73). Progression-free survival (PFS) and overall survival (OS) were compared among different subpopulations with different cancer gene mutations and between patients who received docetaxel +/− ramucirumab versus platinum/taxane-based regimens. Among patients who received docetaxel +/− ramucirumab, the top mutated cancer genes included TP53 (n=167), KRAS (n=127), EGFR (n=65), STK11 (n=32), ERBB2 (HER2) (n=26), etc. None of these cancer gene mutations or PD-L1 expression was associated with PFS or OS. Platinum/taxane-based regimens were associated with a significantly longer mQS (13.00 m, 95% Cl: 11.20–14.80 m versus 8.40 m, 95% Cl: 7.12–9.68 m, LogRank P=0.019) than docetaxel +/− ramcirumab. Key prognostic factors including age, histology, and performance status were not different between these two groups. In conclusion, in patients with metastatic NSCLC who have progressed on platinum doublets and ICIs, the clinical benefit from docetaxel +/− ramucirumab is not associated with the cancer gene mutation status. Platinum/taxane-based regimens may offer a superior clinical benefit over docetaxel +/− ramucirumab in this patient population.
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
Wang, Guoqiao , Li, Yan , Xiong, Chengjie , Gordon, Brian A. , Hassenstab, Jason , Aschenbrenner, Andrew J. , Clifford, David B. , Libre‐Guerra, Jorge J., Shi, Xinyu , Mummery, Catherine J. , Dyck, Christopher H. van , Day, Gregg, Ringman, John M. , Fox, Nick C. , Bittner, Tobias , Team, for the DIAN‐TU Study, Day, Gregory S. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Aschenbrenner, Andrew J , Xiong, Chengjie , Benzinger, Tammie L.S. , McDade, Eric , Lah, James J. , Honig, Lawrence S. , Day, Gregg, Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Delmar, Paul , Bateman, Randall J. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | February 24, 2024 | Volume: 20 | Issue: 4 | Pages: 2698-2706

10.1002/alz.13735 | PMID 38400532 Get It

AbstractINTRODUCTIONIncreasing evidence suggests that amyloid reduction could serve as a plausible surrogate endpoint for clinical and cognitive efficacy. The double‐blind phase 3 DIAN‐TU‐001 trial tested clinical and cognitive declines with increasing doses of solanezumab or gantenerumab.METHODSWe used latent class (LC) analysis on data from the Dominantly Inherited Alzheimer Network Trials Unit 001 trial to test amyloid positron emission tomography (PET) reduction as a potential surrogate biomarker.RESULTSLC analysis categorized participants into three classes: amyloid no change, amyloid reduction, and amyloid growth, based on longitudinal amyloid Pittsburgh compound B PET standardized uptake value ratio data. The amyloid‐no‐change class was at an earlier disease stage for amyloid amounts and dementia. Despite similar baseline characteristics, the amyloid‐reduction class exhibited reductions in the annual decline rates compared to the amyloid‐growth class across multiple biomarker, clinical, and cognitive outcomes.DISCUSSIONLC analysis indicates that amyloid reduction is associated with improved clinical outcomes and supports its use as a surrogate biomarker in clinical trials.Highlights We used latent class (LC) analysis to test amyloid reduction as a surrogate biomarker. Despite similar baseline characteristics, the amyloid‐reduction class exhibited remarkably better outcomes compared to the amyloid‐growth class across multiple measures. LC analysis proves valuable in testing amyloid reduction as a surrogate biomarker in clinical trials lacking significant treatment effects.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Jonasch, Eric, Alva, Ajjai , Bagshaw, H.P. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Johnson, Michael P. , King, Jennifer , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Mortazavi, Amir , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Zibelman, Matthew R. , Schonfeld, Ryan, Stein, MaryElizabeth , Gurski, Lisa A., Motzer, Robert J. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , Carlo, Maria I. , Choueiri, Toni K. , George, Saby , Gore, John L. , Gunn, Andrew, Haas, Naomi B , Johnson, Michael, Kapur, Payal , King, Jennifer, Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Michaelson, M. Dror , Sweis, Randy F.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 4-16

10.6004/jnccn.2024.0008 | PMID 38394781 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.
Methodological and statistical characteristics of meta-analyses on spinal cord stimulation for chronic pain: a systematic review
Kleppel, Donald J , Copeland, Royce , Hussain, Nasir , Wang, Eric J. , D’Souza, Ryan S. , Wang, Eric , D'Souza, Ryan S , Karri, Jay

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 22, 2024 | Volume: 50 | Issue: 4 | Pages: 358-366

10.1136/rapm-2023-105249 | PMID 38388015 Get It

Background A growing number of meta-analyses (MA) have investigated the use of spinal cord stimulation (SCS) as a treatment modality for chronic pain. The quality of these MAs has not been assessed by validated appraisal tools. Objective To examine the methodological characteristics and quality of MAs related to the use of SCS for chronic pain syndromes. Evidence review An online literature search was conducted in Ovid MEDLINE(R), Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, and Scopus databases (January 1, 2000 through June 30, 2023) to identify MAs that investigated changes in pain intensity, opioid consumption, and/or physical function after SCS for the treatment of chronic pain. MA quality was assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) critical appraisal tool. Findings Twenty-five MAs were appraised in the final analysis. Three were considered “high” quality, three “low” quality, and 19 “critically low” quality, per the AMSTAR-2 criteria. There was no association between the publication year and AMSTAR-2 overall quality (β 0.043; 95% CI −0.008 to 0.095; p=0.097). There was an association between the impact factor and AMSTAR-2 overall quality (β 0.108; 95% CI 0.044 to 0.172; p=0.002), such that studies published in journals with higher impact factors were associated with higher overall quality. There was no association between the effect size and AMSTAR-2 overall quality (β −0.168; 95% CI −0.518 to 0.183; p=0.320). According to our power analysis, three studies were adequately powered (>80%) to reject the null hypothesis, while the remaining studies were underpowered (<80%). Conclusions The study demonstrates a critically low AMSTAR-2 quality for most MAs published on the use of SCS for treating chronic pain. Future MAs should improve study quality by implementing the AMSTAR-2 checklist items. PROSPERO registration number CRD42023431155.
Feasibility of a Swine-Based Animal Model for Endoscopic Skull Base Surgery and Reconstruction: An Ex-Vivo and Live Animal Study
Ueki, Yasuhito , Ding, Yong Hong, Moore, Eric J. , Alexander, A. Yohan, Bayraktar, Esref Alperen , Ding, Yonghong , Price, Daniel L. , Pinheiro‐Neto, Carlos

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780371 Get It

Outcomes of Orbit-Sparing Treatment in Olfactory Neuroblastoma with Orbital Involvement: A Retrospective Cohort Study
Graves, Jeffrey P., Stokken, Janalee K., Celda, María Peris, Link, Michael J., Moore, Eric J. , Choby, Garrett, Bauman, Megan M. J. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780316 Get It

Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs in the Chronic Kidney Disease Population: Are They Rational or Reckless?
D’Souza, Ryan S. , D'Souza, Ryan S , Karri, Jay , Wang, Eric J.

Mayo Clinic

Anesthesia & Analgesia | February 21, 2024 | Volume: 139 | Issue: 1 | Pages: 235-237

10.1213/ane.0000000000006574 | PMID 38381665 Get It

Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
Joseph‐Mathurin, Nelly , Feldman, Rebecca L. , Lu, Ruijin , Shirzadi, Zahra , Toomer, Carmen, Clair, Junie R. Saint, Ma, Yinjiao , Strain, Jeremy F. , Kilgore, Collin , Chen, Charles D., Gordon, Brian A. , Chen, Gengsheng , Hornbeck, Russ C. , Massoumzadeh, Parinaz , Wang, Qing , Li, Yan , Wang, Guoqiao , Keefe, Sarah , Schultz, Stephanie A. , Preboske, Gregory M., Jack, Clifford R. , Ances, Beau M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Fulham, Michael , Ghetti, Bernardino , Johnson, Keith A. , Xiong, Chengjie , Oh, Hwamee , Perrin, Richard J. , Ringman, John M. , Saykin, Andrew J. , Supnet, Charlene , Vöglein, Jonathan , Yakushev, Igor , Morris, John C. , Chhatwal, Jasmeer P. , Network, for the Dominantly Inherited Alzheimer, Jack, Clifford R , Gordon, Brian A , Saykin, Andrew J , Day, Gregory S , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Chen, Charles D , Ances, Beau M , Fox, Nick C , Morris, John C , Ghetti, Bernardino F , Supnet-Bell, Charlene , Berman, Sarah , Clair, Junie Saint, McKay, Nicole S. , Friedrichsen, Karl A. , McCullough, Austin , Li, Yan, Cruchaga, Carlos , Llibre‐Guerra, Jorge J. , Allegri, Ricardo , Brooks, William S. , Cash, David M. , Jucker, Mathias , Klunk, William E. , Fougère, Christian la , Niimi, Yoshiki , Reischl, Gerald , Schofield, Peter R. , Su, Yi , Brickman, Adam M. , McDade, Eric , Xiong, Chengjie , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | February 21, 2024 | Volume: 20 | Issue: 4 | Pages: 2680-2697

10.1002/alz.13729 | PMID 38380882 Get It

AbstractINTRODUCTIONAmyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin‐1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre‐/postcodon 200) influences these pathologic features and dementia at different stages.METHODSIndividuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments. We cross‐sectionally evaluated regional Pittsburgh compound B‐positron emission tomography uptake, magnetic resonance imaging markers of SVD (diffusion tensor imaging‐based white matter injury, white matter hyperintensity volumes, and microhemorrhages), and cognition.RESULTSPostcodon 200 carriers had lower amyloid burden in all regions but worse markers of SVD and worse Clinical Dementia Rating® scores compared to precodon 200 carriers as a function of estimated years to symptom onset. Markers of SVD partially mediated the mutation position effects on clinical measures.DISCUSSIONWe demonstrated the genotypic variability behind spatiotemporal amyloidosis, SVD, and clinical presentation in DIAD, which may inform patient prognosis and clinical trials.Highlights Mutation position influences Aβ burden, SVD, and dementia. PSEN1 pre‐200 group had stronger associations between Aβ burden and disease stage. PSEN1 post‐200 group had stronger associations between SVD markers and disease stage. PSEN1 post‐200 group had worse dementia score than pre‐200 in late disease stage. Diffusion tensor imaging‐based SVD markers mediated mutation position effects on dementia in the late stage.